Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 and Anti-CD20 CAR T-Cells in B-cell Malignancies
NCT05797233Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2023
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Hu1928-Hu20BB-Long in B cell lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and Feasibility of Administering CAR T-cells at 30 days. Started Aug 2023; status: active, not recruiting.
02
Drugs
Hu1928-Hu20BB-Long
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05797233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797233.